GlassScriptPhysician profile
Harish Madala
NPI 1639433188
$8,543.85
in general payments reported to CMS, 2019-2025
41 companies · $4,340 in 2025
The $4,340 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,064 · 2020: $85.51 · 2021: $146 · 2022: $203 · 2023: $893 · 2024: $1,812 · 2025: $4,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,445 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,025 · Consulting Fee: $525 · Education: $50.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,444.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,025.31 |
| Consulting Fee | $525.00 |
| Education | $50.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $3,351.23 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $728.89 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Pfizer INC. | $688.55 | 2022-2025 | |
| Janssen Biotech, INC. | $446.38 | 2019-2025 | Darzalex, Talvey, Imbruvica |
| Celgene Corporation | $379.48 | 2019-2025 | Reblozyl |
| Amgen INC. | $368.89 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $282.17 | 2019-2025 | |
| Genentech USA, INC. | $260.28 | 2019-2025 | Lunsumio, Polivy, Phesgo |
| Glaxosmithkline, LLC. | $180.15 | 2021-2024 | Jemperli, Zejula |
| E.R. Squibb & Sons, L.L.C. | $155.11 | 2019-2025 | Opdualag |
| Seagen INC. | $142.94 | 2019-2023 | Padcev, Tukysa |
| Eisai INC. | $141.55 | 2019-2025 | |
| Gilead Sciences, INC. | $127.11 | 2023-2025 | Trodelvy |
| Astellas Pharma US INC | $120.16 | 2023-2025 | Padcev |
| Mirati Therapeutics, INC. | $110.26 | 2023-2024 | Krazati |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harish Madala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.